AUTL Latest Press Releases

-- November 10, 2026 --

Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 Globe Newswire 4:05 PM

Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Globe Newswire 7:00 AM

-- November 9, 2026 --

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference Globe Newswire 7:15 AM

-- November 4, 2026 --

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 Globe Newswire 9:15 AM

-- November 3, 2026 --

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:45 PM

-- October 26, 2026 --

Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026 Globe Newswire 4:15 PM

-- October 5, 2026 --

Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026 Globe Newswire 8:30 AM

-- September 9, 2026 --

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis Globe Newswire 7:00 AM

-- August 11, 2026 --

Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates Globe Newswire 7:00 AM

-- August 3, 2026 --

Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 Globe Newswire 4:05 PM

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors Globe Newswire 7:13 AM

-- July 1, 2026 --

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 25, 2026 --

Autolus Therapeutics to Participate in Upcoming Investor Conference Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes